Trials / Completed
CompletedNCT00259311
Efficacy Study of LY2422347 to Treat Insomnia
A Randomized, Double-Blind Comparison of 5 mg of LY2422347, 15 mg of LY2422347, and Placebo in the Treatment of Patients With Primary Insomnia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 400 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 24 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether a compound known as LY2422347 is effective in treating people diagnosed with primary insomnia (difficulty sleeping with no other significant contributing factor, such as depression).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2422347 | |
| DRUG | placebo |
Timeline
- Start date
- 2005-11-01
- Completion
- 2006-11-01
- First posted
- 2005-11-29
- Last updated
- 2007-01-26
Locations
22 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00259311. Inclusion in this directory is not an endorsement.